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NURUL H . SARKAR, AND HAROLD A . HOFFMAN
(From the Memorial Sloan-Kettering Cancer Center, New York 10021 and the Laboratory ofBiology,
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,
Maryland 20014)
For several reasons the G,X antigen (1) has a prominent place in current work
on murine leukemia virus (MuLV): In the prototype Gl,,+ mouse strain 129, the
G, trait is mendelian, and is expressed selectively (though not exclusively) on
thymocytes . Thus, expression ofthis cell surface component is under the control
of cellular genes and is subject to the controls governing the differentiation of T
lymphocytes (2). Although the 129 mouse produces no demonstrable leukemia
virus such as that found in the AKR strain, it was soon realized that G,X antigen
must in some way be related to MuLV, because productive infection with MuLV
is frequently associated with appearance of G,X antigen on cells that are
genotypically G,x-, most notablyon MuLV-infected rat cells, orcells that belong
to other differentiation pathways (1). The basis of this connection between G,
and MuLV has recently become clear from the demonstration that G,X is one of
the antigens present on gp69/71 (3, 4), the major glycoprotein component ofthe
MuLV envelope. Therefore, our working hypothesis is that the presence of G,
antigen always denotes the presence of gp69/71 (though not all variants of
gp69/71 need necessarily carry G,X).
Study ofthe circumstances under which G,X is expressed on the cell surface is
thus potentially a powerful approach to understanding how the expression of
C-type viral genomes is controlled. Such studies are greatly facilitated by the
availability of mutant and congenic strains ofinbred mice which differ from the
nonmutant or partner strains only with respect to one or another manifestation of
the viral genome.
It is for this reason that we record here (Table I) some details of two G,X
mutant and two G,X congenic stocks derived in our colonies at Memorial
Sloan-Kettering Cancer Center (MSKCC). In addition, to these four strains,
Table I includes data for the three relevant partner strains, and for strain AKR,
forcomparison . These eight strains all differ from one another with respect to one
or more MuLV-related traits .
*This work was supported in part by NCI grants CA-16599 and CA-08748.
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We provide this precis of characteristics of the seven stocks, two mutant and
twocongenic, together with theirthree partner strains, becausethey have already
been valuable in MuLV research (3, 4, 12); the accompanying report exemplifies
their crucial role in elucidating the genetic controls over expression of MuLV
components (13). Descriptive detail is given as footnotes to Table I. The following
points deserve emphasis : It is important to establish that the new strains B6-
G,x+M and BR-G Ix+M are properly classed as mutant rather than genetically
contaminated stocks. The latter is excluded by the concordance of the paired
strains for many genetic markers (Table II) and the fact that they are skin-graft
compatible with the partner strains (10 mo minimal graft observation time). Dis-
tinction of the mutant B6-G I x+M from the congenic B6-G I x+ (derived from 129)
TABLE 11
Typing of G,x Mutant and Congenic Mouse Stocks for Various Biochemical and
Serological Traits
* Chromosome number.
$ Allele.
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poses a special question, because the B6 mutant was segregating in our B6 stock
at the time the B6-G,x+ congenic line was being derived; but nevertheless thetwo
stocks are decisively distinguished by their different levels of expression of G,
on thymocytes ahighly reliableandaccurate criterion. (Itis therefore unnecessary
to dwell on the stringent precautions observed in the maintenance of the
colonies.) No such consideration arises in the case ofthe mutant BR-G,-IM, be-
cause this occurred in stock from Jackson Laboratories, Bar Harbor, Maine. The
term "mutant" implies a stably heritable trait which distinguishes the mutant
stock from the nonmutant stock, whatever the cause. Particularly in the case of
MuLV-related characters it is hazardous to assume that the mechanism fits any
orthodox models ofmutation. On the contrary, the explanation may lie in the ca-
pacity of MuLV genomes to undergo chromosomal integration, and in fact these
Locus 129 129-G,x- B6 B6-G,x+ B6-G,x'M BR BR-G,x+M
Dip-1 (1*) a$ a a a
Id-1 (1) a a b b
Gpd-1 (4) a a a a a a a
Mup-1 (4) b b a a
Pgm-1 (5) a a a a
Ly-2 (6) b b b b b b b
Ly-3 (6) b b b b b b b
Ldr-1 (6) a a a a
Gpi-1 (7) a a b b b a a
Hbb (7) d d s s s s s
Es-1 (8) a a a a
Thy-1 (9) b b b b b b b
Mod-1 (9) b b b b
Es-3 (11) a a a a
H-2 (17) b b b b b k k
Tla (17) c c b b b a a
Ly-1 (19) b b b b b b b
Pca (?) _ _ _ _ _
X-1 (?) + + - - - - -516
￿
STOCKERT ET AL.
￿
BRIEF DEFINITIVE REPORT
mutant stocks may lend themselves especially well to the study of precisely that
phenomenon. Itshould be emphasized thatsimple acquisition ofinfectious MuLV
which would transmit the G, x phenotype independently ofthe germ line does not
fit the facts: (a) We have data showing mendelian segregation of G,x in (BR-
G,x+M x BR) x BRand in the reciprocal backcross (bc).. The ratios of G, x+ seg-
regants in the former cross is 25% (64+/188-), as is the case ofcomparable back-
crosses involving 129 (1), indicating similarly that two loci (Gv-1 and Gv-2 if the
same two loci are involved) are concerned in the BR-G,x+M mutation. Segrega-
tion data are not yet available for B6-G,x+M, but the stable inheritance of this
mutation through five typed generations, and the tracing of its ancestry, suggest
that mendelian ratios will be found. (b) Neither mutant strain has yielded mouse-
tropic virus of the AKR type with high spontaneous inducibility, and in BR-
G,x+M no virions have been seen in electromicrographs . Also, neither mutant
stock has the Gross cell surface antigen (GCSA) nor expresses G,x antigen in
spleen, unlike AKR and other mice producing large amounts ofAKR-type virus.
The finding of C-type virions in electromicrographs of thymus and spleen of
both B6-G,+ and B6-G,x +M is noteworthy: While they are far fewer than in
AKR they nevertheless constitute an apparently consistent distinction from B6,
from 129, and from BR. With regard toB6-G,x+ we can point to the new evidence
that B6 expresses a particular variant of MuLV-gp69/71 glycoprotein (G,x- type)
on its thymocytes, whereas 129 mice express a different MuLV-gp69/71 variant
(G,x+ type), the two being coded or controlled by different loci that are not
closely linked (13). Thus, B6-G,x+ evidently carries information from two MuLV
genomes, one from each parental stock. This circumstance may (a) account for
the augmented production of gp69/71 and p30 by B6-G,+ (Table I), and (b)
suggest that the appearance of virions in B6-G,x + is due to interaction between
the two MuLV genomes, as RAV-0 (an avian C-type virus) may be produced in
chicken by crossbred progeny of parents incapable of producing RAV-0 (14).
Our finding that 129 differs from 129-G, x- in expressing not only gp69/71 but
also p30 parallels other data (12) and allows the interpretation (12) that G,x+
gp69/71 and p30 of 129 may be coded by linked genes of the Gv-1 locus (1),
implying further that Gv-1 is an MuLV genome.
Received for publication 6 March 1975.
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